2025年即将收官，今年首批成立的26只浮动费率基金陆续交出阶段性答卷。尽管运作时间均不足一年， 但业绩已呈现出显著分化。其中，广发价值稳进A的业绩表现引人注目。 | | | | 首批26只浮动费率基金今年以来业绩表现 | | | | | --- | --- | --- | --- | --- | --- | --- | | 序号 | 证券代码 | 证券简称 | 成立以来回报(%) | 非变潮榆(仅) | 非金经理 | 基金成立日 | | 1 | 024459.OF | 华商致远回报A | 58.90 | 28.38 | 张明听 | 2025/7/15 | | 2 | 024473.OF | 信澳优势行业A | 36.86 | 15.40 | 吴清宇 | 2025/7/23 | | 3 | 024450.OF | 易方达成长进取A | 34.98 | 19.25 | 刘健维 | 2025/6/19 | | 4 | 024433.OF | 嘉实成长共赢A | 32.88 | 4.06 | 李涛 | 2025/6/19 | | 5 | 024454.OF | 景顺长城成长同行 | 23.96 | 13.81 | ...

Core Insights - The first batch of floating fee rate funds has shown significant performance differentiation, highlighting the varying capabilities of fund managers in terms of positioning, sector allocation, and market judgment [1][9] Performance Overview - As of December 16, 2025, out of 26 funds, 19 achieved positive returns while 7 reported negative returns. The top performer, Huashang Zhiyuan Return A, delivered a remarkable return of 58.90%, followed by Xin'ao Advantage Industry A at 36.86% and E Fund Growth Progress A at 34.98% [2][10] - Other notable performers include Jiashi Growth Win A and Invesco Great Wall Growth, both exceeding 23% returns. Conversely, funds like Guangfa Value Steady A and Yinhua Growth Smart A reported negative returns of -8.32% and -3.35%, respectively [2][10] - The overall distribution of fund returns is characterized by a "middle large, both ends small" pattern, with most funds yielding between -0.1% and 7% [2][10] Fund Size and Performance Relationship - Notably, high-performing funds are not exclusively large. Huashang Zhiyuan Return A, with a size of 2.838 billion yuan, is the largest, while Jiashi Growth Win A, with a size of 406 million yuan, achieved a return of 32.88%, demonstrating the agility of smaller funds in volatile markets [2][10] Investment Strategies - Top-performing funds tend to focus on high-growth sectors. For instance, Huashang Zhiyuan Return A has concentrated holdings in AI computing-related stocks, with significant contributions from stocks like Zhongji Xuchuang and Shijia Photon, which saw increases of 45.39% and 40.17% over the past three months [3][11] - Xin'ao Advantage Industry A has a high concentration in semiconductor storage, with key stocks like Demingli and Jiangbolong rising by 55.43% and 119.02%, respectively. However, this strategy also led to volatility, as some holdings experienced declines of 13% to 21% [5][13] - E Fund Growth Progress A adopts a more balanced approach, diversifying across sectors such as optical communication and consumer electronics, successfully capturing gains from leading stocks [6][15] Underperforming Funds - Underperforming funds often remain focused on traditional industries or deviate from market trends. Guangfa Value Steady A has a significant allocation to liquor stocks, which have generally declined over 10% in the past three months, contrasting sharply with the strong performance of technology sectors [7][16] - Yinhua Growth Smart A is heavily invested in the real estate sector and certain pharmaceutical stocks, with some holdings experiencing declines as steep as 44.58%, indicating a lack of timely adjustments to market shifts [8][17] Conclusion - The short-term performance of the first batch of floating fee rate funds reflects a collision of different investment strategies and market styles in 2025. Funds aligned with the technology growth narrative performed strongly, while those focused on traditional value or balanced strategies lagged behind [9][17]

Core Insights - The active management equity funds are experiencing a strong recovery in returns, with 95% achieving positive returns and an average return exceeding 15% as of August 7, 2025 [1][2] - The pharmaceutical sector has emerged as the biggest winner, with four funds doubling their returns, all focused on this industry [3] Fund Performance - As of August 7, 2025, the average return for over 4,500 active equity funds is 15.03%, while more than 93% of over 2,500 stock index funds have positive returns averaging 11.8% [2] - Active equity funds have outperformed major indices like CSI 300 (4.6%) and CSI 500 (10.6%) after three years of underperformance [2] Fund Manager Dynamics - There are 90 active equity fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading at over 50 billion yuan [5][6] - Among these managers, 86 have achieved positive returns, with the average return for those managing over 30 billion yuan being 9.8%, which is lower than the average of the top 90 managers [6] Sector Focus - The four funds that doubled their returns are primarily invested in the pharmaceutical sector, including Changcheng Pharmaceutical Industry Selection and Huashan Pharmaceutical Biotechnology [3] - The top-performing managers, Zhang Wei and Zhang Lu, have focused on themes like innovative drugs and robotics, contributing to their high returns of 65.8% and 53.4% respectively [8] Underperforming Funds - Despite the overall positive trend, 228 active equity funds reported negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [3] - Wang Mingxu from GF Fund has seen 7 out of 8 funds underperform, with a bottom return of -7.4% [8][9] Investor Sentiment - Although the A-share market has been rising, investor confidence in active equity funds remains low, with a significant reduction in total shares of active equity funds by approximately 198.24 billion shares in the first half of 2025 [3]

Group 1 - The core viewpoint of the articles indicates a strong recovery in the performance of actively managed equity funds in 2025, with 95% of these funds achieving positive returns and an average return exceeding 15% as of August 7 [2][3] - The pharmaceutical sector has emerged as the biggest winner, with four actively managed equity funds achieving returns that have doubled this year, all focusing on the pharmaceutical industry [4][5] - As of mid-2025, there are 90 fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading with over 50 billion yuan under management [8][9] Group 2 - The average return of actively managed equity funds has outperformed major stock indices, such as the CSI 300 and the CSI 500, which recorded returns of 4.6% and 10.6% respectively [3] - The average return of the entire market of over 4,500 actively managed equity funds is 15.03%, compared to 11.8% for over 2,500 stock index funds [3] - Despite the overall positive performance, there are still 228 actively managed equity funds with negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [4][6] Group 3 - The top-performing funds in the pharmaceutical sector include Changcheng Pharmaceutical Industry Selection, Bank of China Hong Kong Stock Connect Pharmaceutical, Yongying Pharmaceutical Innovation Selection, and Huashan Pharmaceutical Biotechnology, all achieving significant returns [4][5] - The performance of fund managers varies significantly, with some, like Zhang Wei and Zhang Lu, achieving returns of 65.8% and 53.4% respectively, while others, such as Wang Mingxu, have negative returns [12][13] - The total scale of actively managed equity funds reached 3.39 trillion yuan by mid-2025, although the total number of shares decreased by 198.24 billion compared to the end of the previous year [6][7]

Group 1 - The A-share market has shown resilience in the second quarter, with the Shanghai Composite Index rebounding 9.2% from its low of 3040.69 points on April 7 to 3381.58 points by June 23 [1] - There is significant performance differentiation among newly established funds, with a gap exceeding 46 percentage points due to varying investment strategies and timing of market entry [2][3] - The healthcare sector, particularly innovative drugs, has been a key driver of fund performance, with some funds achieving returns over 20% despite market volatility [3] Group 2 - The second quarter has seen a notable increase in the issuance of equity funds, with over half of the 247 newly established products raising funds in less than 15 days, indicating a rush to capitalize on market opportunities [5] - The market is currently characterized by both opportunities and risks, with sectors like AI, humanoid robots, and innovative drugs showing high local interest, although some companies may still face valuation challenges [6][8] - The overall valuation of the A-share market remains historically low, supported by a dual easing monetary and fiscal policy environment, while uncertainties from global trade tensions pose risks [8]